MA28176A1 - Inhibiteurs de la forme mutante du kit - Google Patents

Inhibiteurs de la forme mutante du kit

Info

Publication number
MA28176A1
MA28176A1 MA29054A MA29054A MA28176A1 MA 28176 A1 MA28176 A1 MA 28176A1 MA 29054 A MA29054 A MA 29054A MA 29054 A MA29054 A MA 29054A MA 28176 A1 MA28176 A1 MA 28176A1
Authority
MA
Morocco
Prior art keywords
kit
inhibitors
mutant form
mutant
administered
Prior art date
Application number
MA29054A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28176A1 publication Critical patent/MA28176A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Inhibiteurs de la forme mutante de la KIT La présente invention concerne le traitement de maladies dépendantes de la KIT qui sont caractérisées par une forme mutante de la KIT, dans laquelle la KIT mutante est identifiée et un inhibiteur approprié de la KIT mutante, sélectionné parmi la midostaurine, le vatalanib et un composé A, est administré.
MA29054A 2003-11-18 2006-05-24 Inhibiteurs de la forme mutante du kit MA28176A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18

Publications (1)

Publication Number Publication Date
MA28176A1 true MA28176A1 (fr) 2006-09-01

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29054A MA28176A1 (fr) 2003-11-18 2006-05-24 Inhibiteurs de la forme mutante du kit

Country Status (27)

Country Link
US (3) US8017621B2 (fr)
EP (2) EP1686997B1 (fr)
JP (3) JP4762150B2 (fr)
KR (1) KR101153647B1 (fr)
CN (3) CN101693031A (fr)
AT (1) ATE428426T1 (fr)
AU (1) AU2004290902B2 (fr)
BR (1) BRPI0416680A (fr)
CA (1) CA2546189C (fr)
CY (1) CY1110354T1 (fr)
DE (1) DE602004020654D1 (fr)
DK (1) DK1686997T3 (fr)
ES (1) ES2324917T3 (fr)
HR (1) HRP20090390T1 (fr)
IL (2) IL175578A (fr)
MA (1) MA28176A1 (fr)
MX (1) MXPA06005598A (fr)
NO (1) NO20062694L (fr)
NZ (1) NZ547195A (fr)
PL (1) PL1686997T3 (fr)
PT (1) PT1686997E (fr)
RU (2) RU2362562C2 (fr)
SG (1) SG139747A1 (fr)
SI (1) SI1686997T1 (fr)
TN (1) TNSN06138A1 (fr)
WO (1) WO2005049032A1 (fr)
ZA (1) ZA200603905B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
JP4762150B2 (ja) 2003-11-18 2011-08-31 ノバルティス アーゲー Ｋｉｔの変異体の阻害剤
EP1799226A1 (fr) * 2004-08-31 2007-06-27 Novartis AG Utilisation de midostaurine pour le traitement de tumeurs du stroma gastro-intestinal
CN101171013A (zh) 2005-05-02 2008-04-30 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
RU2415672C2 (ru) * 2005-05-02 2011-04-10 Новартис Аг Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
ES2391199T3 (es) * 2005-12-06 2012-11-22 Novartis Ag Derivados de pirimidilaminobenzamida para el tratamiento de neurofibromatosis
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20100298338A1 (en) * 2008-01-23 2010-11-25 Yanfeng Wang Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit
US9801880B2 (en) 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (fr) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 Amorces, sondes et kit destinés à être utilisés pour détecter les mutations du gène c-kit
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0672035A1 (fr) 1993-10-01 1995-09-20 Novartis AG Derives pyrimidineamine et leurs procedes de preparation
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (fr) 1997-06-06 1998-12-10 Baylor College Of Medicine Mecanisme secretoire des mastocytes utilise comme cible en vue du developpement de medicaments antiallergiques
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ES2326500T3 (es) 1997-11-13 2009-10-13 Mowycal Lending, Llc Pequeños peptidos y metodos para el tratamiento del asma y la inflamacion.
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
US20040157855A1 (en) 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
EP1401429A2 (fr) 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
WO2003076660A1 (fr) * 2002-03-13 2003-09-18 F.Hoffmann-La Roche Ag Procede pour selectionner des facteurs determinant la sensibilite a des medicaments et procede pour predire la sensibilite a des medicaments a partir des facteurs ainsi selectionnes
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CN100467064C (zh) * 2003-09-19 2009-03-11 诺瓦提斯公司 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
JP4762150B2 (ja) 2003-11-18 2011-08-31 ノバルティス アーゲー Ｋｉｔの変異体の阻害剤
CN101171013A (zh) 2005-05-02 2008-04-30 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
JP2013241438A (ja) 2013-12-05
IL175578A (en) 2013-10-31
WO2005049032A1 (fr) 2005-06-02
CA2546189C (fr) 2013-04-23
US20070213317A1 (en) 2007-09-13
HRP20090390T1 (hr) 2009-08-31
JP4762150B2 (ja) 2011-08-31
CN102274230A (zh) 2011-12-14
ATE428426T1 (de) 2009-05-15
EP1686997A1 (fr) 2006-08-09
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
SI1686997T1 (sl) 2009-08-31
BRPI0416680A (pt) 2007-02-13
US20120157441A1 (en) 2012-06-21
US8124611B2 (en) 2012-02-28
RU2006121447A (ru) 2008-01-10
CN101693031A (zh) 2010-04-14
HK1093680A1 (en) 2007-03-09
NO20062694L (no) 2006-06-12
CN102274230B (zh) 2015-07-01
AU2004290902A1 (en) 2005-06-02
CA2546189A1 (fr) 2005-06-02
US20100179179A1 (en) 2010-07-15
KR101153647B1 (ko) 2012-06-18
PL1686997T3 (pl) 2009-09-30
AU2004290902B2 (en) 2008-09-25
JP2011121973A (ja) 2011-06-23
NZ547195A (en) 2010-06-25
MXPA06005598A (es) 2006-08-11
IL175578A0 (en) 2008-04-13
SG139747A1 (en) 2008-02-29
RU2009110449A (ru) 2010-09-27
TNSN06138A1 (fr) 2007-11-15
KR20060101761A (ko) 2006-09-26
EP1686997B1 (fr) 2009-04-15
CN1882344A (zh) 2006-12-20
IL229124A0 (en) 2013-12-31
DK1686997T3 (da) 2009-07-27
PT1686997E (pt) 2009-07-17
ZA200603905B (en) 2008-11-26
JP2007511567A (ja) 2007-05-10
RU2405553C1 (ru) 2010-12-10
US8017621B2 (en) 2011-09-13
EP1917965A1 (fr) 2008-05-07
RU2362562C2 (ru) 2009-07-27
DE602004020654D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
IL229124A0 (en) Inhibitors with a mutant form of kit
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ECSP045429A (es) Combinacion de compuestos organicos
ATE414697T1 (de) Nf-kb-inhibitoren
NO20034056D0 (no) Proliferative sykdommer
CO5611137A2 (es) Composiciones de clorhidrato de naltrexona
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60118953D1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
ATE471315T1 (de) Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ECSP055844A (es) Nuevos compuestos triciclicos
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
EP1488808A4 (fr) Remedes contre les maladies glomerulaires
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DK1569650T3 (da) Anvendelse af levocetirizin til behandling af vedvarende rhinitis allergica
DE50214750D1 (de) Kinase inhibitoren und deren verwendung
NO20071936L (no) Polymorfer av cysteinproteaseinhibitoren N-(1-cyanosyklopropyl)-3-syklopropylmetansulfonyl-2(R)-(2,2,2-trifluor-1(S)-(4-fluorfenyl)etylamino)propionamid